Dean Y. Li - 04 Feb 2026 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Role
Executive VP & President, MRL
Signature
/s/ Kelly E. W. Grez as Attorney-in-Fact for Dean Y. Li
Issuer symbol
MRK
Transactions as of
04 Feb 2026
Net transactions value
-$946,349
Form type
4
Filing time
06 Feb 2026, 16:12:16 UTC
Previous filing
28 Jan 2026
Next filing
10 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Li Dean Y Executive VP & President, MRL MERCK & CO., INC., 126 EAST LINCOLN AVENUE, RAHWAY /s/ Kelly E. W. Grez as Attorney-in-Fact for Dean Y. Li 06 Feb 2026 0001837016

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRK Common Stock Options Exercise $845,475 +15,087 +15% $56.04 117,357 04 Feb 2026 Direct
transaction MRK Common Stock Sale $1,791,824 -15,087 -13% $118.77 102,270 04 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRK Stock Option (Right to Buy) Options Exercise $0 -15,087 -100% $0.000000 0 04 Feb 2026 Common Stock 15,087 $56.04 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.7200 to $118.8300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
F3 The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021.